ClinicalTrials.gg
RecruitingNCT07163689TIPS-PSVDUpdated Nov 19, 2025

TIPS for Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease

An observational study in TIPS, Portal Hypertension and Porto-Sinusoidal Vascular Disease, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Primary conditionEsophageal and Gastric VaricesRegistry: Hypertension, PortalReclassifiedWhy we changed it
Registry
Hypertension, Portal — the first condition term the registry derived for this study.
ClinicalTrials.gg
Esophageal and Gastric Varices
Why
  1. The study's listed conditions name Esophageal and Gastric Varices, a narrower term within Hypertension, Portal.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Universitaire, Amiens · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
360
Ages
18 Years and older
Sex
All
01

Study summary

Porto-sinusoidal Vascular Disease (PSVD) is characterized by a portal hypertension (PH) without cirrhosis. This can induce PH complications, like digestive hemorrhage from esophageal or gastric varices, ascites, or even portal thrombosis. Due to the rarity of MVPS, the treatment of complications of portal hypertension is modeled on the methods used in cirrhotic portal hypertension with non-cardio-selective beta blockers, endoscopic ligations or diuretics in first line therapy, as proposed by the Baveno VII recommendations. In complicated or refractory forms of PH in PSVD, the place of TIPS is also discussed, as in the field of cirrhosis. However, the experience of TIPS in PSVD is limited, reported in case reports and small specifically dedicated series. No predictive factors for survival or recurrence and tolerance were well known. A larger study with control group is needed in order to better know the right time and the right indication for the use of TIPS in complicated PH PSVD-related.

The study will be retrospective, multicentric involving tertiary university French centers, expert in the management of TIPS. Patients white TIPS-PSVD will be compared with historical patients with TIPS-cirrhose, matched on age, sexe, indication of TIPS. The study will not comprise new intervention, only observational in a real life condition

02

Conditions studied

  • TIPS
  • Portal Hypertension
  • Porto-Sinusoidal Vascular Disease
  • Refractory Ascite
  • Esophageal Varices
  • Gastrointestinal Hemorrhage

Browse trials for

Keywords

  • TIPS
  • Portal hypertension
  • Porto-Sinusoidal Vascular disease
  • refractory ascite
  • esophageal varices
  • gastrointestinal hemorrhage
03

In context

Esophageal and Gastric Varices Reclassified

150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.

This study's planned enrollment of 360 is above the median of 130 across 44 observational studies indexed under Esophageal and Gastric Varices.

Browse Esophageal and Gastric Varices studies →

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.

Compared within Esophageal and Gastric Varices, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Portal. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be retrospective and observational, collecting data provided in 24 tertiary french University Hospital (CHU).

All patients with PSVD with a PH and treated by TIPS will be included (group TIPS_PSDV) and compared with an historical group of patients with Cirrhosis with a TIPS (group TIPS-cirrhose).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PSVD group :
  • Patient with PSVD according VALDIG criteria
  • TIPS for digestive hemorrhage on portal hypertension
  • TIPS for ascite
  • TIPS for portal vein thrombosis
  • Cirrhosis group with PH : (appaired by age, sexe, type of PH complications)
  • Confirmed cirrhosis with :
  • TIPS for digestive hemorrhage on portal hypertension
  • TIPS for refractory ascite
  • TIPS for portal vein thrombosis

Exclusion criteria

Exclusion Criteria:

  • no PSVD confirmed diagnosis
  • Budd Chiari syndrome
  • Rendu Osler disease; Heart failure
  • Fontan; Sarcoïdosis
  • Schistosomiase
  • Congenitale liver fibrosis
  • Abernathy syndrome
  • Tumor infiltration by lymphoma
  • Bone graft
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
360 participants (estimated)
Patient registry
No

Groups and cohorts

  • group TIPS-PSVD

    experimental group

  • TIPS-cirrhose

    historical control group

06

What researchers measure

Primary outcomes

  1. overall survival after TIPS placement

    Time frame: at 3 months

  2. overall survival after TIPS placement

    Time frame: at 6 months

  3. overall survival after TIPS placement

    Time frame: at 1 year

  4. overall survival after TIPS placement

    Time frame: at 2 years

  5. overall survival after TIPS placement

    Time frame: at 3 years

  6. overall survival after TIPS placement

    Time frame: at 4 years

  7. overall survival after TIPS placement

    Time frame: at 5 years

Secondary outcomes

  1. free portal hypertension hemorrhage recurrence survival

    Time frame: at 3 months

  2. free portal hypertension hemorrhage recurrence survival

    Time frame: at 6 months

  3. free portal hypertension hemorrhage recurrence survival

    Time frame: at 1 year

  4. free portal hypertension hemorrhage recurrence survival

    Time frame: at 2 years

  5. free portal hypertension hemorrhage recurrence survival

    Time frame: at 3 years

  6. free portal hypertension hemorrhage recurrence survival

    Time frame: at 4 years

  7. free portal hypertension hemorrhage recurrence survival

    Time frame: at 5 years

  8. free ascite recurrence survival

    Time frame: at 3 months

  9. free ascite recurrence survival

    Time frame: at 6 months

  10. free ascite recurrence survival

    Time frame: at 1 year

  11. free ascite recurrence survival

    Time frame: at 2 years

  12. free ascite recurrence survival

    Time frame: at 3 years

  13. free ascite recurrence survival

    Time frame: at 4 years

  14. free ascite recurrence survival

    Time frame: at 5 years

  15. free TIPS dysfunction survival

    Time frame: at 3 months

  16. free TIPS dysfunction survival

    Time frame: at 6 months

  17. free TIPS dysfunction survival

    Time frame: at 1 year

  18. free TIPS dysfunction survival

    Time frame: at 2 years

  19. free TIPS dysfunction survival

    Time frame: at 3 years

  20. free TIPS dysfunction survival

    Time frame: at 4 years

  21. free TIPS dysfunction survival

    Time frame: at 5 years

  22. complication of TIPS placement at D0

    Time frame: at 3 months

  23. complication of TIPS placement at D0

    Time frame: at 6 months

  24. complication of TIPS placement at D0

    Time frame: at 1 year

  25. complication of TIPS placement at D0

    Time frame: at 2 years

  26. complication of TIPS placement at D0

    Time frame: at 3 years

  27. complication of TIPS placement at D0

    Time frame: at 4 years

  28. complication of TIPS placement at D0

    Time frame: at 5 years

07

Study locations

1 of 1 sites recruiting
  • CHU Amiens Picardie
    Amiens, Picardie 80054, France
    Recruiting
    • Eric NGUYEN KHAC, PhD · Contactnguyen-khac.eric@chu-amiens.fr · +33322668883
    • Marika Rudler, MD · Principal investigator
    • Florent Artru, MD · Principal investigator
    • Pierre Emmanuel Rautou, MD · Principal investigator
    • Christophe Bureau, MD · Principal investigator
    • Laure Elkrief, MD · Principal investigator
    • Jean Paul CERVONI, MD · Principal investigator
    • Jérome Dumortier, MD · Principal investigator
    • Jean Charles Nault, MD · Principal investigator
    • Magdalena MESZAROS, MD · Principal investigator
    • Géraldine DAHLQVIST, MD · Principal investigator
    • Térésa ANTONINI, MD · Principal investigator
    • Christine SILVAIN, MD · Principal investigator
    • Rodolphe ANTY, MD · Principal investigator
    • Giuliana AMADDEO, MD · Principal investigator
    • Nicolas CARBONELL, MD · Principal investigator
    • Odile GORIA, MD · Principal investigator
    • Audrey COILLY, MD · Principal investigator
    • Jerome GOURNAY, MD · Principal investigator
    • Théophile GERSTER, MD · Principal investigator
    • Paul HERBAMESSIERE, MD · Principal investigator
    • Noémie REBOUX, MD · Principal investigator
    • Armando ABERGEL, MD · Principal investigator
    • Dominique CAZALS-HATEM, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2025
First posted
Sep 9, 2025
StartActual
May 16, 2025
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07163689
Collaborators
Groupe Hospitalier Pitie-Salpetriere, Rennes University Hospital, AP-HP - HU BEAUJON, University Hospital, Toulouse, CHRU TOURS, Centre Hospitalier Universitaire de Besancon, Hospices Civils de Lyon, France, APHP - HOPITAL AVICENNE, University Hospital, Montpellier, Saint-Luc University Hospital, CHU Poitiers, Centre Hospitalier Universitaire de Nice, CH HENRI MONDOR, Saint Antoine University Hospital, University Hospital, Rouen, Hopital Paul Brousse, Nantes University Hospital, Centre Hospitalier Universitaire Dijon, University Hospital, Bordeaux, University Hospital, Brest, University Hospital, Clermont-Ferrand
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
May 16, 2025
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 19, 2025

Study contacts

Eric NGUYEN-KHAC, Pr
Contact
nguyen-khac.eric@chu-amiens.fr
33+3 22 08 88 51

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion